Explore

Trendline Trendline
Knicks Legends Energize Fans at Nassau County NBA Finals Rally

Knicks Legends Energize Fans at Nassau County NBA Finals Rally

Knicks Legends Energize Fans at Nassau County NBA Finals Rally
Trendline Trendline
New Long Island Show Celebrates Fashion Icon Halston's Legacy

New Long Island Show Celebrates Fashion Icon Halston's Legacy

New Long Island Show Celebrates Fashion Icon Halston's Legacy
Trendline Trendline
Knicks Legends Rally Fans Ahead of NBA Finals in Nassau County

Knicks Legends Rally Fans Ahead of NBA Finals in Nassau County

Knicks Legends Rally Fans Ahead of NBA Finals in Nassau County
Rapid Read Rapid Read
Islanders' Anders Lee Leads Successful Kan Jam Event for Cancer Support

Islanders' Anders Lee Leads Successful Kan Jam Event for Cancer Support

Anders Lee, a forward for the New York Islanders, participated in a Kan Jam fundraising event at Syosset High School in Long Island, New York. The event, organized by the Jam Kancer in the Kan Foundation, raised over $56,000 to support families affected by cancer. Lee, who has been involved with the foundation since 2016, was inspired by Fenov Pierre-Louis, a young cancer patient whose story motivated him to engage in charitable activities. The event saw significant participation from students, who collectively raised funds through intrinsic motivation and community spirit. The initiative also included the Fenov Memorial Scholarship, which awards $2,000 annually to high school seniors who have supported cancer patients.
Rapid Read Rapid Read
Riverhead Town Board Approves Eminent Domain to Acquire Long Island Science Center Building

Riverhead Town Board Approves Eminent Domain to Acquire Long Island Science Center Building

The Riverhead Town Board has voted to proceed with eminent domain proceedings to seize the Long Island Science Center building located on East Main Street. This decision, made by a 3-1 vote, is part of the town's broader downtown revitalization efforts. The board's decision comes despite objections from Supervisor Jerry Halpin, who argued that eminent domain should be a last resort. The building, which has been vacant since its purchase in 2019, is seen as a blight on Main Street and a hindrance to the Town Square project. The board's resolution states that acquiring the property will benefit the public by removing blight and furthering economic redevelopment. The Long Island Science Center had previously presented a two-phase expansion plan but has not moved forward with renovations, leading to doubts about the project's viability.
Rapid Read Rapid Read
NYU Langone Health Study Reveals Widening Income Disparities in Lung Cancer Survival

NYU Langone Health Study Reveals Widening Income Disparities in Lung Cancer Survival

Researchers from NYU Langone Health's Perlmutter Cancer Center presented findings at the 2026 ASCO Annual Meeting, highlighting a significant increase in the survival gap between high- and low-income counties since the introduction of lung cancer screening guidelines in 2013. The study, led by Dr. Daniel J. Becker, analyzed nearly 1 million lung cancer cases diagnosed between 2005 and 2022. It found that while lung cancer screening has improved early diagnosis and survival rates across all income groups, the benefits have been disproportionately greater in wealthier communities. This has resulted in a 12.2 percent larger survival gap in the screening era compared to the years before the guidelines were adopted.
Rapid Read Rapid Read
Molloy University Implements Hands-on CPR Training for Lifesaving Skills

Molloy University Implements Hands-on CPR Training for Lifesaving Skills

Molloy University on Long Island is offering hands-on CPR training to its students, emphasizing the importance of lifesaving skills. CBS News New York's Jenna DeAngelis reports on how the university is teaching this critical technique. The training sessions are designed to equip participants with the knowledge and confidence to perform CPR in emergency situations. This initiative is part of a broader effort to enhance public health and safety by ensuring more individuals are prepared to respond effectively in emergencies.
Rapid Read Rapid Read
Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

A clinical trial has demonstrated the potential of a personalized mRNA vaccine in reducing the recurrence of melanoma. Conducted by researchers at NYU Langone Health, the trial involved 157 patients in Australia and the U.S. who had undergone surgery to remove their tumors. The study combined the mRNA vaccine with Keytruda, an immunotherapy drug, and showed that 68.8% of patients remained cancer-free after five years, compared to 49.1% who received Keytruda alone. The results, presented at the American Society of Clinical Oncology conference, highlight the vaccine's ability to train T cells to recognize and target specific neoantigens, enhancing the immune system's response to cancer.
Rapid Read Rapid Read
NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

A study led by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of a vaccine, intismeran, and the immunotherapy drug pembrolizumab (Keytruda) can significantly reduce the risk of melanoma recurrence and death. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The results, presented at the 2026 annual meeting of the American Society of Clinical Oncology, showed that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to the standard treatment of pembrolizumab alone. Additionally, the combination therapy reduced the risk of distant metastasis by 59%. The study highlights the potential of mRNA vaccines like intismeran in enhancing the effectiveness of immunotherapy for cancers with high mutation rates.
Rapid Read Rapid Read
Woman Arrested in Connection with Fatal Stabbing in Massapequa Home

Woman Arrested in Connection with Fatal Stabbing in Massapequa Home

A 22-year-old woman has been arrested following a fatal stabbing incident in a Massapequa home on Long Island. The Nassau County police responded to a 911 call early Monday morning and discovered a 28-year-old man with a stab wound, who was pronounced dead at the scene. The incident prompted a significant police presence, including helicopters and search dogs, as authorities conducted a thorough investigation. Neighbors reported being awakened by the commotion and police activity. The relationship between the victim and the suspect remains unclear, though a relative mentioned they were acquaintances. The victim lived with his parents in the Massapequa home.
Rapid Read Rapid Read
NYU Langone Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49% Over Five Years

NYU Langone Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49% Over Five Years

A study led by NYU Langone Health has demonstrated that a combination of the intismeran vaccine and pembrolizumab significantly reduces the risk of melanoma recurrence and death by 49% over five years. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The combination therapy showed a 68.8% cancer-free rate compared to 49.1% in the pembrolizumab-alone group. The study, presented at the ASCO 2026 Annual Meeting, highlights the potential of mRNA vaccines in enhancing immunotherapy effectiveness against melanoma.
Rapid Read Rapid Read
NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows mRNA Vaccine Reduces Melanoma Recurrence by 49%

A recent study conducted by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of an mRNA-based vaccine, intismeran, and the immunotherapy drug pembrolizumab significantly reduces the risk of melanoma recurrence and death. The study involved 107 patients who had undergone melanoma surgery and were randomly selected to receive the combination therapy. Results showed a 49% reduction in the risk of cancer recurrence or death compared to a control group receiving only pembrolizumab. The study, known as KEYNOTE-942, was presented at the American Society of Clinical Oncology's annual meeting and published in the Journal of Clinical Oncology. The vaccine works by teaching the immune system to recognize and attack cancer cells, utilizing T cells to target specific neoantigens produced by melanoma cells.